Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Biohaven Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Biohaven şirketinin kazançları yıllık ortalama -32.8% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.7% oranında arttı.

Anahtar bilgiler

-32.8%

Kazanç büyüme oranı

-10.8%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	n/a
Özkaynak getirisi	-194.6%
Net Marj	n/a
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Sep 23

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Jul 26

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

May 18

Gelir ve Gider Dağılımı

Biohaven nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NYSE:BHVN Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	-747	80	701
31 Mar 24	-517	76	466
31 Dec 23	-408	63	373
30 Sep 23	-465	97	370
30 Jun 23	-431	120	229
31 Mar 23	-544	126	327
31 Dec 22	-570	131	333
30 Sep 22	-421	64	342
30 Jun 22	-407	57	336
31 Mar 22	-257	47	205
31 Dec 21	-214	37	181

Kaliteli Kazançlar: BHVN şu anda kârlı değil.

Büyüyen Kar Marjı: BHVN şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: BHVN kârlı değildir ve zararlar son 5 yılda yılda 32.8% oranında artmıştır.

Büyüme Hızlandırma: BHVN 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: BHVN kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 0.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: BHVN hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -194.56% ) sahiptir.

Biohaven Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Recent updates

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $250.000005 million.

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $250.000005 million.

Price target increased by 9.2% to US$62.36

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Consensus EPS estimates fall by 21%

New major risk - Financial position

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Independent Director recently bought US$1.0m worth of stock

Chief Scientific Officer recently bought US$1.0m worth of stock

Independent Director recently bought US$996k worth of stock

Biohaven Ltd. Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas Including Immunology, Neuroscience, Metabolic Disorders and Oncology At Annual Investor R&D Day

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

New minor risk - Share price stability

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

Consensus EPS estimates fall by 23%

Independent Director recently bought US$1.0m worth of stock

Independent Director recently bought US$999k worth of stock

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $230.000037 million.

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

Now 21% overvalued after recent price rise

Biohaven Ltd., Annual General Meeting, Apr 30, 2024

Now 21% overvalued after recent price rise

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

New major risk - Financial position

Director exercised options and sold US$460k worth of stock

Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)

Price target increased by 11% to US$33.17

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Price target increased by 7.8% to US$30.00

Price target increased by 7.4% to US$29.00

Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

Independent Director recently bought US$402k worth of stock

Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True

Biohaven Ltd. Announces Positive Data from its Exploratory Electroencephalogram Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies

Independent Director recently bought US$922k worth of stock

Biohaven's Valuation Challenge: Weighing Potential Against Setbacks

Independent Director recently bought US$2.0m worth of stock

New minor risk - Share price stability

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Biohaven: A Promising Investment In Innovative Neurological Therapies

Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Biohaven's spinal muscular atrophy therapy gets FDA fast track status

High number of new and inexperienced directors

Biohaven Ltd: Assessing The Spinoff

Biohaven Non-GAAP EPS of -$1.25

Chairman & CEO recently bought US$2.1m worth of stock

Biohaven Ltd. Advances Development of the MoDE Platform Technology Licensed From Yale University

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin